KALV
KalVista Pharmaceuticals, Inc. Common Stock
stockNASDAQ
InactiveJun 10, 2026
27.00USD+0.037%(+0.01)4,272,770
Loading…
Loading…
Sector
Healthcare
Industry
Biotechnology
CEO
Thomas Crockett
HQ
Cambridge, Massachusetts, USA
Nov 22, 2016 · 1-for-14 (reverse)
KALV Profile
kalvista is a clinical stage pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors.
KALV Performance
| Period | Price | Date | Change |
|---|